Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1.

PMID:
31576004
2.

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C.

Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.

3.

A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy.

Watts JM, Perez A, Pereira L, Fan YS, Brown G, Vega F, Petrie K, Swords RT, Zelent A.

Int J Mol Sci. 2017 Jul 11;18(7). pii: E1492. doi: 10.3390/ijms18071492.

4.

Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.

Sbirkov Y, Kwok C, Bhamra A, Thompson AJ, Gil V, Zelent A, Petrie K.

Int J Mol Sci. 2017 Jul 5;18(7). pii: E1440. doi: 10.3390/ijms18071440.

5.

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C.

Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.

6.

Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.

Gil VS, Bhagat G, Howell L, Zhang J, Kim CH, Stengel S, Vega F, Zelent A, Petrie K.

Dis Model Mech. 2016 Dec 1;9(12):1483-1495. Epub 2016 Oct 28.

7.

Acute leukemia in adult Hispanic Americans: a large-population study.

Swords R, Sznol J, Elias R, Watts J, Zelent A, Martin E, Vargas F, Bethel-Ellison S, Kobetz E.

Blood Cancer J. 2016 Oct 14;6(10):e484. doi: 10.1038/bcj.2016.94. No abstract available.

8.

Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells.

Kwon YJ, Leibovitch BA, Bansal N, Pereira L, Chung CY, Ariztia EV, Zelent A, Farias EF, Waxman S.

Oncotarget. 2016 Aug 19;8(51):88421-88436. doi: 10.18632/oncotarget.11381. eCollection 2017 Oct 24.

9.

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.

Bansal N, Bosch A, Leibovitch B, Pereira L, Cubedo E, Yu J, Pierzchalski K, Jones JW, Fishel M, Kane M, Zelent A, Waxman S, Farias E.

Oncotarget. 2016 Jul 12;7(28):43689-43702. doi: 10.18632/oncotarget.9905.

10.

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.

Bansal N, Petrie K, Christova R, Chung CY, Leibovitch BA, Howell L, Gil V, Sbirkov Y, Lee E, Wexler J, Ariztia EV, Sharma R, Zhu J, Bernstein E, Zhou MM, Zelent A, Farias E, Waxman S.

Oncotarget. 2015 Oct 27;6(33):34087-105. doi: 10.18632/oncotarget.6048.

11.

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases.

McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F.

Epigenetics Chromatin. 2015 Sep 24;8:38. doi: 10.1186/s13072-015-0030-8. eCollection 2015.

12.

Is the Relationship Between Breastfeeding and Childhood Risk of Asthma and Obesity Mediated by Infant Antibiotic Treatment?

Krenz-Niedbała M, Kościński K, Puch EA, Zelent A, Bręborowicz A.

Breastfeed Med. 2015 Jul-Aug;10(6):326-33. doi: 10.1089/bfm.2014.0173. Epub 2015 Jun 25.

PMID:
26110340
13.

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Kwon YJ, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L, Gil V, Christova R, Bansal N, Yang S, Sharma R, Ariztia EV, Frankum J, Brough R, Sbirkov Y, Ashworth A, Lord CJ, Zelent A, Farias E, Zhou MM, Waxman S.

Mol Cancer Ther. 2015 Aug;14(8):1824-36. doi: 10.1158/1535-7163.MCT-14-0980-T. Epub 2015 Jun 15.

14.

Unlocking the potential of retinoic acid in anticancer therapy.

Schenk T, Stengel S, Zelent A.

Br J Cancer. 2014 Nov 25;111(11):2039-45. doi: 10.1038/bjc.2014.412. Epub 2014 Nov 20. Review.

15.

Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells.

Kaluza D, Kroll J, Gesierich S, Manavski Y, Boeckel JN, Doebele C, Zelent A, Rössig L, Zeiher AM, Augustin HG, Urbich C, Dimmeler S.

Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):533-43. doi: 10.1161/ATVBAHA.112.300415. Epub 2013 Jan 3.

PMID:
23288173
16.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA Jr, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A.

Nat Med. 2012 Mar 11;18(4):605-11. doi: 10.1038/nm.2661.

17.

Histone deacetylases 9 and 10 are required for homologous recombination.

Kotian S, Liyanarachchi S, Zelent A, Parvin JD.

J Biol Chem. 2011 Mar 11;286(10):7722-6. doi: 10.1074/jbc.C110.194233. Epub 2011 Jan 18.

18.

Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.

Farias EF, Petrie K, Leibovitch B, Murtagh J, Chornet MB, Schenk T, Zelent A, Waxman S.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11811-6. doi: 10.1073/pnas.1006737107. Epub 2010 Jun 14.

19.

LIM protein Ajuba functions as a nuclear receptor corepressor and negatively regulates retinoic acid signaling.

Hou Z, Peng H, White DE, Negorev DG, Maul GG, Feng Y, Longmore GD, Waxman S, Zelent A, Rauscher FJ 3rd.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2938-43. doi: 10.1073/pnas.0908656107. Epub 2010 Jan 26.

20.

LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis.

Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, Luzzatto L, Teruya-Feldstein J, Weiss MJ, Pandolfi PP.

Dev Cell. 2009 Oct;17(4):527-40. doi: 10.1016/j.devcel.2009.09.005.

21.

PLZF is a regulator of homeostatic and cytokine-induced myeloid development.

Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE.

Genes Dev. 2009 Sep 1;23(17):2076-87. doi: 10.1101/gad.1788109.

22.

Differentiation therapy of acute myeloid leukemia: past, present and future.

Petrie K, Zelent A, Waxman S.

Curr Opin Hematol. 2009 Mar;16(2):84-91. doi: 10.1097/MOH.0b013e3283257aee. Review.

PMID:
19468269
23.

Fingering modulators of retinoic acid signaling identifies new prognostic marker for neuroblastoma.

Gronemeyer H, Zelent A.

Cancer Cell. 2009 Apr 7;15(4):249-51. doi: 10.1016/j.ccr.2009.03.012.

24.

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. doi: 10.1073/pnas.0813280106. Epub 2009 Feb 18.

25.

Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics.

Zelent A, Petrie K, Boix-Chornet M, Melnick AM, Waxman S, Gore SD.

Cancer Res. 2008 Jul 1;68(13):4967-70. doi: 10.1158/0008-5472.CAN-07-6779. No abstract available.

26.

Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters.

Petrie K, Guidez F, Zhu J, Howell L, Owen G, Chew YP, Parks S, Waxman S, Licht J, Mittnacht S, Zelent A.

Oncogene. 2008 Sep 4;27(39):5260-6. doi: 10.1038/onc.2008.159. Epub 2008 May 26.

PMID:
18504436
27.

Marked for death.

Petrie K, Zelent A.

Nat Cell Biol. 2008 May;10(5):507-9. doi: 10.1038/ncb0508-507. No abstract available.

PMID:
18454129
28.

Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology.

Delva L, Zelent A, Naoe T, Fenaux P, Waxman S, Degos L, Chomienne C.

Cancer Res. 2007 Nov 15;67(22):10635-7. Epub 2007 Nov 9. No abstract available.

29.

DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia.

Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S, Enver T, Hildebrandt G, Zelent A.

Blood. 2008 Feb 15;111(4):2374-7. Epub 2007 Nov 9.

PMID:
17993618
30.

Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation.

Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, So CW.

Cancer Cell. 2007 Jul;12(1):36-51.

31.

Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF.

Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP.

Science. 2007 May 11;316(5826):860-6.

32.

Histone deacetylase inhibitors in APL and beyond.

Petrie K, Prodromou N, Zelent A.

Curr Top Microbiol Immunol. 2007;313:157-203. Review.

PMID:
17217044
33.

Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor.

Zheng Y, Balasubramanyam K, Cebrat M, Buck D, Guidez F, Zelent A, Alani RM, Cole PA.

J Am Chem Soc. 2005 Dec 14;127(49):17182-3.

PMID:
16332055
34.

Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop.

Zelent A, Petrie K, Lotan R, Waxman S, Gore SD.

Mol Cancer Ther. 2005 Nov;4(11):1810-9.

35.

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.

Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, Zelent A, de Thé H, Gronemeyer H.

Cancer Res. 2005 Oct 1;65(19):8754-65.

37.

Benzodithiophenes induce differentiation and apoptosis in human leukemia cells.

Jing Y, Hellinger N, Xia L, Monks A, Sausville EA, Zelent A, Waxman S.

Cancer Res. 2005 Sep 1;65(17):7847-55.

38.

Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.

Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Hormaeche I, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A.

Mol Cell Biol. 2005 Jul;25(13):5552-66.

39.

APL and differentiation therapy--joint international congress.

Zelent A.

IDrugs. 2001 Nov;4(11):1257-62.

PMID:
15942830
40.

Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy.

Zelent A, Petrie K, Chen Z, Lotan R, Lübbert M, Tallman MS, Ohno R, Degos L, Waxman S.

Cancer Res. 2005 Feb 15;65(4):1117-23.

41.

Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.

Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP.

Nature. 2005 Jan 20;433(7023):278-85.

42.

Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwar N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali S.

Gene Ther. 2005 Mar;12(5):452-60. Erratum in: Gene Ther. 2005 Mar;12(6):552. Sarwarl, N [corrected to Sarwar, N]. Gene Ther. 2005 May;12(10):862.

PMID:
15647773
43.

Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways.

Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A.

Blood. 2005 Jan 1;105(1):341-9. Epub 2004 Aug 31.

PMID:
15339853
44.

Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor.

Pike J, Holmes D, Kamalati T, Davies D, Tolhurst R, Mazhar D, Fishpool S, al-Jehani R, Waxman J, Zelent A, Lemoine NR, Ali S, Buluwela L.

Oncogene. 2004 Sep 30;23(45):7561-70.

PMID:
15334066
45.

State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003.

Zelent A, Waxman S, Carducci M, Wright J, Zweibel J, Gore SD.

Clin Cancer Res. 2004 Jul 15;10(14):4622-9.

46.

Cross talk between retinoic acid signaling and transcription factor GATA-2.

Tsuzuki S, Kitajima K, Nakano T, Glasow A, Zelent A, Enver T.

Mol Cell Biol. 2004 Aug;24(15):6824-36.

47.

Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia.

Zelent A, Greaves M, Enver T.

Oncogene. 2004 May 24;23(24):4275-83. Review.

PMID:
15156184
48.

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.

Sun Y, Kim SH, Zhou DC, Ding W, Paietta E, Guidez F, Zelent A, Ramesh KH, Cannizzaro L, Warrell RP, Gallagher RE.

Leukemia. 2004 Jul;18(7):1258-69.

PMID:
15116119
49.

Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.

Sirulnik A, Melnick A, Zelent A, Licht JD.

Best Pract Res Clin Haematol. 2003 Sep;16(3):387-408. Review.

PMID:
12935958
50.

Regulation of Hoxb2 by APL-associated PLZF protein.

Ivins S, Pemberton K, Guidez F, Howell L, Krumlauf R, Zelent A.

Oncogene. 2003 Jun 12;22(24):3685-97.

PMID:
12802276

Supplemental Content

Loading ...
Support Center